MedTrace Logo

a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)

NCT02911194 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-09-05

No results posted yet for this study

Summary

Under double-blind, placebo-controlled, cross-over conditions, the short-term effects of use of A1 beta casein free milk (a2 milk) and milk containing A1 beta casein will be compared in a sample of pre-pubescent boys diagnosed with an autism spectrum disorder (ASD) with concurrent features of attention-deficit hyperactivity disorder (ADHD).

Conditions

Interventions

DIETARY_SUPPLEMENT

a2 milk

replace all milk with a2 milk

DIETARY_SUPPLEMENT

a1 containing milk

use a1 containing milk

Sponsors & Collaborators

  • ESPA Research

    collaborator UNKNOWN

  • a2 Milk Company Ltd.

    collaborator INDUSTRY

  • Northumbria University

    lead OTHER

Principal Investigators

  • John K Lodge, PhD · Northumbria University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
5 Years
Max Age
10 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02911194 on ClinicalTrials.gov